Malacidin A has no observed toxicity or haemolytic effect on mammalian cells at concentrations of up to 100-250 ?g/mL, over 100 times the MIC for affected pathogens A33312.
Malacidin A, along with DB14052, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria A33312. Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin A appears to act via its own distinct mechanism.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Malacidin A. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Malacidin A. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Malacidin A. |
| Dicoumarol | The risk or severity of bleeding can be increased when Malacidin A is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Malacidin A is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Malacidin A is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Malacidin A is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Malacidin A is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Malacidin A is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Malacidin A is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Malacidin A is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Malacidin A is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Malacidin A is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Malacidin A is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Malacidin A is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Malacidin A is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Malacidin A is combined with (S)-Warfarin. |
| Lactulose | The therapeutic efficacy of Lactulose can be decreased when used in combination with Malacidin A. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Malacidin A. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Malacidin A. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Quinisocaine. |
| Cisatracurium | Malacidin A may increase the neuromuscular blocking activities of Cisatracurium. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Malacidin A is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Malacidin A. |